Valuation: Viyash Scientific Limited

Market Cap 110B 1.15B 1B 943M 861M 1.62B 1.62B 11.32B 4.37B 56.07B 4.31B 4.22B 181B P/E 2027 *
35.9x
P/E 2028 * 21.7x
Enterprise Value 110B 1.15B 1B 943M 861M 1.62B 1.62B 11.32B 4.37B 56.07B 4.31B 4.22B 181B EV / Sales 2027 *
2.82x
EV / Sales 2028 * 2.46x
Free-Float
32.8%
Yield 2027 *
-
Yield 2028 * -
1 day+1.73%
1 week+7.14%
Current month-2.98%
1 month-6.18%
3 months-3.43%
6 months+42.25%
Current year+22.94%
1 week 237.95
Extreme 237.95
262.5
1 month 236.85
Extreme 236.85
279.8
Current year 178.4
Extreme 178.4
297.9
1 year 178.4
Extreme 178.4
297.9
3 years 88.39
Extreme 88.39
297.9
5 years 61.8
Extreme 61.8
297.9
10 years 42.45
Extreme 42.45
336.4
Manager TitleAgeSince
Chief Executive Officer 62 16/12/2025
Director of Finance/CFO - 01/01/2026
Chief Tech/Sci/R&D Officer - 05/02/2026
Director TitleAgeSince
Chairman 78 25/08/2025
Director/Board Member 67 25/08/2020
Director/Board Member 57 11/04/2022
Change 5-day change 1-year change 3-year change Capi.($)
+1.73%+7.14%+26.00%+176.32% 1.15B
+0.45%+3.00%+55.00%+112.54% 1,043B
-0.10%+0.74%+54.52%+67.72% 649B
+0.28%+0.82%+19.15%+73.63% 469B
-0.19%+0.97%+34.30%+45.99% 355B
+0.28%+2.30%+18.47%+26.67% 270B
+0.89%+4.59%+10.19%+14.72% 262B
+4.34%+9.21%+43.44%+53.25% 222B
+1.40%+4.35%+35.72%+103.53% 189B
-0.46%-6.20%-32.46%-59.65% 175B
Average +0.83%+2.16%+26.43%+61.47% 363.42B
Weighted average by Cap. +0.49%+2.19%+36.39%+67.24%

Financials

2027 *2028 *
Net sales 38.99B 408M 356M 335M 306M 574M 574M 4.02B 1.55B 19.91B 1.53B 1.5B 64.2B 44.68B 467M 408M 384M 350M 658M 658M 4.61B 1.78B 22.82B 1.76B 1.72B 73.56B
Net income 3.44B 35.97M 31.43M 29.54M 26.96M 50.6M 50.61M 355M 137M 1.76B 135M 132M 5.66B 5.4B 56.44M 49.32M 46.35M 42.3M 79.39M 79.41M 556M 215M 2.76B 212M 207M 8.88B
Net Debt - -
Logo Viyash Scientific Limited
Viyash Scientific Limited, formerly SeQuent Scientific Limited, is an India-based integrated pharmaceutical company with a global footprint, operating in the domains of animal health (active pharmaceutical ingredients (APIs), and finished dosage formulations) and analytical services. The Company has eight manufacturing facilities, based in India, Turkey, Brazil, Spain and Germany. It is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It specializes in analytical and bioanalytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It offers analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer-developed methods or in-house method development.
Employees
2,900
Date Price Change Volume
23/09/26 255.90 +1.73% 33,799
22/09/26 ₹251.55 -0.10% 403,837
21/09/26 ₹251.80 +0.76% 74,647
18/09/26 ₹249.90 +2.08% 70,642
17/09/26 ₹244.80 +2.49% 136,362
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
251.55INR
Average target price
322.25INR
Spread / Average Target
+28.11%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VIYASH Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!